Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDC00164

Target Information
NameDual specificity mitogen-activated protein kinase kinase    
Type of targetClinical trial target    
SynonymsERK activator kinase    
MAP kinase kinase    
MAPKK    
MEK    
DiseaseCancer, unspecific
[ICD9: 140-229   ICD10: C00-C96]
[1]
Heart failure
[ICD9: 428   ICD10: I50]
[1]
Immunodeficiency
[ICD9: 279.3   ICD10: D84.9]
[1]
Inflammation[1]
Proliferative diseases[1]
Psoriasis
[ICD9: 696   ICD10: L40]
[1]
Restenosis[1]
Stroke
[ICD9: 434.91   ICD10: I61-I63]
[1]
Drug(s)RG7421+RG7204Phase IIIMetastatic melanoma BRAF mutation positive
ARRY-162Phase IIMalignant melanoma (BRAFV600E or NRAS mutations) (see also solid tumors)
AZD6244Phase IINon Small Cell Lung Cancer/Melanoma[2]
BAY 86-9766Phase IIFirst-line liver cancer
E6201Phase IIPsoriasis
GSK1120212Phase IISolid Tumors and Lymphoma[3]
MEK-InhibitorPhase IICancer
MEK162Phase IIMelanoma
BAY 86-9766Phase I/IIFirst-line pancreatic cancer
GDC-0973Phase IbSolid tumours[4]
ARRY-162Phase ILate-stage solid tumors (see also skin)
ARRY-300Phase ICancer
AZD8330Phase ISolid tumours[2]
Anti-MekPhase ICancer[5]
GDC-0623Phase ISolid tumours[6]
MSC2015103BPhase ISolid Tumors
RG7167Phase ISolid Tumors
RG7167Phase ISolid tumors
RG7304Phase ISolid tumors
RG7420Phase ISolid tumors
SAR245408/MSC1936369B combination therapyPhase ISolid Tumors
SAR245409/MSC1936369B combination therapyPhase ISolid Tumors
TAK-733Phase ISolid Tumors
TAK-733Phase ISolid tumors
PD-0325901Terminated in Phase ISolid tumours[7]
PD-0325901Terminated in Phase IINSCLC, melanoma, breast, colon cancer[7]
Related US Patent6,310,060
6,440,966
6,455,582
6,469,004
6,506,798
6,638,945
Target ValidationClick to Find Target Validation Information.    
InhibitorAZD6244[2]
AZD8330[2]
Anti-Mek[5]
GDC-0623[6]
GDC-0973[4]
GSK1120212[3]
PD-0325901[7]
U-0126[8]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. To Reference
Ref 2AstraZeneca. Product Development Pipeline. January 29 2009. To Reference
Ref 3GSK. Product Development Pipeline. February 2009. To Reference
Ref 42011 Pipeline of Genentech. To Reference
Ref 5Roche. Product Development Pipeline. July 29 2009. To Reference
Ref 62011 Pipeline of Genentech. To Reference
Ref 7A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 8Biochem J. 2000 Oct 1;351(Pt 1):95-105.Specificity and mechanism of action of some commonly used protein kinase inhibitors. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543